UnitedHealth Group revised its 2025 earnings outlook to $24.65-$25.15 per share (net) and $26-$26.50 per share (adjusted), following first-quarter adjusted earnings of $7.20 per share.
02
First-quarter 2025 revenues grew by $9.8 billion year-over-year to $109.6 billion, with earnings from operations reaching $9.1 billion.
03
The company returned nearly $5 billion to shareholders in Q1 2025 through dividends and share repurchases, achieving a 26.8% return on equity.
04
UnitedHealthcare increased its consumers served by 780,000 year-to-date, while Optum Health expects to serve 650,000 new value-based care patients in 2025.
05
The medical care ratio increased to 84.8% in Q1 2025 from 84.3% in Q1 2024, primarily due to Medicare funding reductions and higher senior care activity, partially offset by Medicare Part D program changes.
06
The operating cost ratio improved to 12.4% in Q1 2025 from 14.1% in Q1 2024, driven by Part D program revenue impacts and increased operating efficiencies.
07
Optum Rx revenues reached $35.1 billion, with adjusted scripts growing to 408 million compared to 395 million in the prior year.
Insights
01
UnitedHealth Group revised its 2025 earnings outlook to $24.65-$25.15 per share (net) and $26-$26.50 per share (adjusted), following first-quarter adjusted earnings of $7.20 per share.
02
First-quarter 2025 revenues grew by $9.8 billion year-over-year to $109.6 billion, with earnings from operations reaching $9.1 billion.
03
The company returned nearly $5 billion to shareholders in Q1 2025 through dividends and share repurchases, achieving a 26.8% return on equity.
04
UnitedHealthcare increased its consumers served by 780,000 year-to-date, while Optum Health expects to serve 650,000 new value-based care patients in 2025.
05
The medical care ratio increased to 84.8% in Q1 2025 from 84.3% in Q1 2024, primarily due to Medicare funding reductions and higher senior care activity, partially offset by Medicare Part D program changes.
06
The operating cost ratio improved to 12.4% in Q1 2025 from 14.1% in Q1 2024, driven by Part D program revenue impacts and increased operating efficiencies.
07
Optum Rx revenues reached $35.1 billion, with adjusted scripts growing to 408 million compared to 395 million in the prior year.